Veranova A CDMO that manages complexity with confidence

Veranova A CDMO that manages complexity with confidence

X

[{"orgOrder":0,"company":"Codexis","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Codexis and Nestl\u00e9 Health Science Sign Development Agreement to Advance Therapeutic Candidate towards Clinical Studies and Extend Strategic Collaboration Agreement","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Discovery"},{"orgOrder":0,"company":"Codexis","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"$6.0 million","newsHeadline":"Codexis Earns Milestone Payment from GlaxoSmithKline","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"Codexis","sponsor":"Merck & Co. Inc.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Codexis and Merck Amend and Extend Supply Agreement for Enzyme Used in Manufacture of Sitagliptin","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Codexis","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codexis and Nestl\u00e9 Health Science Initiate a Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I"},{"orgOrder":0,"company":"Codexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codexis Presents Pre-Clinical Data Highlighting its Programs in Homocystinuria and Maple Syrup Urine Disease at ICIEM 2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical"},{"orgOrder":0,"company":"Codexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codexis to Present Data Highlighting Three Gene Therapy Programs at the ASGCT 25th Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery"},{"orgOrder":0,"company":"Codexis","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codexis Presents Pre-Clinical Data Highlighting Gene Therapy Programs at the ASGCT 25th Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical"},{"orgOrder":0,"company":"Codexis","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Codexis Announces Agreement with Pfizer to Supply Enzyme for the Manufacture of PAXLOVID (Nirmatrelvir Tablets;Ritonavir Tablets)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Codexis","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codexis and Nestl\u00e9 Health Science Announce Interim Results from Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I"}]

Find Clinical Drug Pipeline Developments & Deals by Codexis

Codexis
Developments
Full Screen View

Codexis

About, Contact Details

EVENTS

Webinars & Exhibitions

Webinars & Exhibitions

PRESENTATION(s)

No Presentations

VIDEO(s)

No Video

DIGITAL CONTENT

68 News

68 News

DEVELOPMENTS

9 Drug(s) in Development

9 Drug(s) in Development

Developments

Filters

×

FILTER:

filter

Company

filter

Sponsor

filter

Country

filter

Therapeutic Area

filter

Study Phase

Active Filter(s):

Filters

Reset Filter

All Developments

Companies By Therapeutic Area

Development Status

Codexis

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Codexis and Nestlé Health Science Announce Interim Results from Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency

Details:

CDX-7108 is an orally administered therapeutic lipase enzyme variant specifically engineered to overcome the limitations of existing pancreatic enzyme replacement therapy (PERT). PERT is the main treatment for exocrine pancreatic insufficiency (EPI).

Lead Product(s): CDX-7108

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CDX-7108

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Nestle Health Sciences SA

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 23, 2023

ASK
US

Upload
your Pipeline Activity

Codexis

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Codexis Announces Agreement with Pfizer to Supply Enzyme for the Manufacture of PAXLOVID (Nirmatrelvir Tablets;Ritonavir Tablets)

Details:

The unique enzyme is an important element in the manufacture of PAXLOVID™ (ritonavir) and plays a role in supporting the efforts to ensure rapid availability of this COVID-19 oral treatment to people around the world.

Lead Product(s): Nirmatrelvir,Ritonavir

Therapeutic Area: Infections and Infectious Diseases Product Name: Paxlovid

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Pfizer Inc

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 14, 2022

ASK
US

Upload
your Pipeline Activity

Codexis

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Codexis Presents Pre-Clinical Data Highlighting Gene Therapy Programs at the ASGCT 25th Annual Meeting

Details:

Pre-clinical data highlights enzyme variants engineered with Codexis’ CodeEvolver® platform to offer potentially improved efficacy as compared to current enzymes when administered as transgenes in gene therapies for Hemophilia A, Fabry Disease, and Pompe Disease.

Lead Product(s): CDX-6316

Therapeutic Area: Genetic Disease Product Name: CDX-6316

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Takeda Pharmaceutical

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 16, 2022

ASK
US

Upload
your Pipeline Activity

Codexis

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Codexis to Present Data Highlighting Three Gene Therapy Programs at the ASGCT 25th Annual Meeting

Details:

Two poster to be presentated highlighting three of the Company’s gene therapy programs using directed evolution to potentially improve treatment options for Hemophilia A and lysosomal storage diseases.

Lead Product(s): Undisclosed

Therapeutic Area: Genetic Disease Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 02, 2022

ASK
US

Upload
your Pipeline Activity

Codexis

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Codexis Presents Pre-Clinical Data Highlighting its Programs in Homocystinuria and Maple Syrup Urine Disease at ICIEM 2021

Details:

CDX-6512, a gastrointestinal-stable methionine-gamma-lyase as a potential orally-administered enzyme therapy for homocystinuria, which demonstrated up to a 45% suppression in serum total homocysteine.

Lead Product(s): CDX-6512

Therapeutic Area: Genetic Disease Product Name: CDX-6512

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 22, 2021

ASK
US

Upload
your Pipeline Activity

Codexis

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Codexis and Nestlé Health Science Initiate a Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency

Details:

CDX-7108 is a lipase variant specifically engineered to overcome the limitations of traditional pancreatic enzyme replacement therapy (PERT) deficiencies. CDX-7108 is highly stable to the acidic conditions in the stomach and resistant to proteases in the upper intestines.

Lead Product(s): CDX-7108

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CDX-7108

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Nestle Health Sciences SA

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 03, 2021

ASK
US

Upload
your Pipeline Activity

Codexis

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Codexis and Merck Amend and Extend Supply Agreement for Enzyme Used in Manufacture of Sitagliptin

Details:

Under a research and development agreement, Codexis and Merck leveraged Codexis’ CodeEvolver® enzyme engineering platform technology to design a novel, proprietary enzyme to serve as a biocatalyst in the sitagliptin manufacturing process.

Lead Product(s): Sitagliptin Phosphate

Therapeutic Area: Endocrinology Product Name: Januvia

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Merck & Co. Inc.

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement September 09, 2021

ASK
US

Upload
your Pipeline Activity

Codexis

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Codexis Earns Milestone Payment from GlaxoSmithKline

Details:

This milestone marks the advancement of the commercialization of an enzyme, generated using CodeEvolver under the licensing agreement, that is engineered to improve a key step in the manufacturing process for a currently undisclosed drug.

Lead Product(s): Undisclosed

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Undisclosed

Partner/Sponsor/Collaborator: GSK

Deal Size: $25.0 million Upfront Cash: $6.0 million

Deal Type: Collaboration July 07, 2021

ASK
US

Upload
your Pipeline Activity

Codexis

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Codexis and Nestlé Health Science Sign Development Agreement to Advance Therapeutic Candidate towards Clinical Studies and Extend Strategic Collaboration Agreement

Details:

The companies’ new agreement will advance the development of CDX-7108, the lead candidate for a potential treatment of a GI disorder.

Lead Product(s): CDX-7108

Therapeutic Area: Gastroenterology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Nestle Health Sciences SA

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration January 10, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY